What Is the Optimal Surgical Approach to Thymectomy in Myasthenia Gravis?
This meta-analysis of studies comparing 2 or more surgical approaches vs thymectomy aimed to identify the best option for myasthenia gravis patients.
This meta-analysis of studies comparing 2 or more surgical approaches vs thymectomy aimed to identify the best option for myasthenia gravis patients.
A team of researchers assessed the safety, efficacy, and tolerability of efgartigimod for the treatment of patients with generalized myasthenia gravis.
A team of investigators evaluated the relationship between changes in AChR Ab levels induced by immunosuppressive treatment and myasthenia gravis prognosis at 1-year following treatment in patients with the disease.
Efgartigimod may be an effective and well-tolerated treatment option for patients with myasthenia gravis.
Investigators evaluated the characteristics and risk factors for neurologic adverse events associated with immune checkpoint inhibitors.
Investigators assessed the safety and efficacy of tacrolimus monotherapy as an initial approach for patients with drug-naïve myasthenia gravis.
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
A panel of international experts provided new evidence-based recommendations for the management of myasthenia gravis, including new guidance for thymectomy and medical treatment.
There was a rapid and sustained clinical response in patients treated with eculizumab for anti-acetylcholine receptor-positive refractory generalized myasthenia gravis.
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.